Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma
Journal of Investigative Dermatology · 2025
DOI: 10.1016/j.jid.2025.03.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Liya Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois, USA. Hauptthemen laut MEDLINE: Melanoma, GTP Phosphohydrolases, Skin Neoplasms, Ubiquitin-Specific Peptidase 7. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Southern Illinois University School of Medicine, Alberta Innovates.
Abstract (Originalsprache)
Targeted therapy for NRAS-mutant melanoma remains an unmet clinical need. We found that inhibiting USP7 with the selective ubiquitin-specific protease 7 inhibitor (USP7i) FT671 inhibited cell proliferation in NRAS-mutant melanoma cell lines. In addition, we identified and validated that knockout of TP53BP1, TP53, or CDKN1A conferred resistance to FT671, suggesting that the activation of a functional p53 signaling pathway is essential for the efficacy of USP7i. In Nras-mutant melanoma isograft models, FT671 treatment delayed tumor growth. Moreover, the combinatorial treatment with FT671 and MAPK/(extracellular signal-regulated kinase) kinase 1/2 inhibitor was synergistic and induced pyroptosis in vitro. In immunocompetent mice, the combined treatment profoundly suppressed tumor growth, prolonged survival, and enhanced intratumoral immune cell infiltration, particularly increasing the ratios of CD8+ T cells and mature dendritic cells, indicative of activated antitumor immunity. Notably, the triple combination of USP7i, MAPK/(extracellular signal-regulated kinase) kinase 1/2 inhibitor, and anti-PD-1 antibody resulted in durable tumor regression, with effects persisting beyond 80 days after treatment cessation. These findings establish USP7i + MAPK (extracellular signal-regulated kinase) kinase 1/2 inhibitor as a promising strategy for targeting NRAS, an 'undruggable' mutation in melanoma, and provide a strong rationale for the clinical development of USP7i plus MAPK (extracellular signal-regulated kinase) kinase 1/2 inhibitor as an adjuvant therapy to enhance anti-PD-1 immunotherapy in patients with NRAS-mutant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
- Department of Mathematics and Statistics, Faculty of Science, University of Calgary, Calgary, Canada.
- Department of Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois, USA; Simmons Cancer Institute, Southern Illinois University School of Medicine, Sp…
- Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Rut…
- Department of Mathematics and Statistics, Faculty of Science, University of Calgary, Calgary, Canada; Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, Canada; Alberta Children's Hospital R…
Förderung
- NIA NIH HHS
- Southern Illinois University School of Medicine
- Alberta Innovates
- NSERC
- NIH
Zitieren
APA
Su, L., Wang, D., Purwin, T. J., Ran, S., Yang, Q., Zhang, Q., & Cai, W. (2025). Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2025.03.021
Vancouver
Su L, Wang D, Purwin TJ, Ran S, Yang Q, Zhang Q, et al. Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2025.03.021
BibTeX
@article{Su2025,
author = {Su, Liya and Wang, Dinghao and Purwin, Timothy J and Ran, Sophia and Yang, Qi and Zhang, Qingrun and Cai, Weijia},
title = {Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma},
journal = {Journal of Investigative Dermatology},
year = {2025},
doi = {10.1016/j.jid.2025.03.021}
}
EUVIMED